Natixis Advisors, L.P. Crinetics Pharmaceuticals, Inc. Transaction History
Natixis Advisors, L.P.
- $53.5 Billion
- Q4 2024
A detailed history of Natixis Advisors, L.P. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 45,683 shares of CRNX stock, worth $1.67 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45,683
Previous 44,346
3.01%
Holding current value
$1.67 Million
Previous $2.27 Million
3.09%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding CRNX
# of Institutions
252Shares Held
89.2MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$333 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.95MShares$254 Million0.07% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$228 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$225 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$198 Million0.03% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.97B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...